Pegylated liposomal doxorubicin (PEG-LD) and paclitaxel in patients with metastatic breast carcinoma: A phase II study

被引:0
|
作者
Leonardi, V. [1 ]
Palmisano, V. [1 ]
Pepe, A. [1 ]
Savio, G. [1 ]
Laudani, A. [1 ]
De Bella, M. Tamburo [1 ]
Mesi, L. [1 ]
Agostana, B. [1 ]
机构
[1] ARNAS Civico, Dipartimento Oncol, Div Med Oncol, Palermo, Italy
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:144 / 144
页数:1
相关论文
共 50 条
  • [1] Pegylated liposomal doxorubicin (PEG-LD) and paclitaxel in patients with metastatic breast carcinoma: A phase II study
    Leonardi, V
    Palmisano, V
    Pepe, A.
    Usset, A.
    Savio, G.
    Laudani, A.
    Calabria, C.
    Giresi, A.
    Carruba, G.
    Agostara, B.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI10 - XI10
  • [2] Pegylated liposomal doxorubicin (Peg-LD) and paclitaxel in patients with metastatic breast carcinoma: A phase II study
    Leonardi, Vita
    Palmisano, Valentina
    Pepe, Alessio
    Usset, Antonella
    Savio, Giuseppina
    Laudani, Agata
    Calabria, Caterina
    Rondello, Giacomo
    Carruba, Giuseppe
    Agostara, Biagio
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 85 - 85
  • [3] Pegylated liposomal doxorubicin (Peg-LD) and paclitaxel in patients with metastatic breast carcinoma:: A phase II study.
    Winograd, B
    Leonardi, V
    Palmisano, V
    Pepe, A
    Savio, G
    Laudani, A
    Blasi, L
    Alù, M
    Rondello, G
    Cusimano, MP
    Agostara, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 98S - 98S
  • [4] WEEKLY PACLITAXEL AND PEGYLATED LIPOSOMAL DOXORUBICIN (PEG-LD) AS FRONT LINE THERAPY IN PATIENTS WITH METASTATIC BREAST CARCINOMA
    Palmisano, V.
    Leonardi, V.
    Pepe, A.
    Mesi, L.
    Gugliuzza, M.
    Cianna, C. S.
    Calabria, C.
    Stefano, R.
    Agostara, B.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 25 - 25
  • [5] Weekly Paclitaxel and Pegylated Liposomal Doxorubicin (PEG-LD) as front line therapy in patients with metastatic breast carcinoma
    Palmisano, Valentina
    Leonardi, Vita
    Pepe, Alessio
    Mesi, Lino
    Rondello, Giacomo
    Scianna, Caterina
    Laudani, Agata
    Calabria, Caterina
    Savio, Giuseppina
    Agostara, Biagio
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 44 - 44
  • [6] Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study
    Leonardi, Vita
    Palmisano, Valentina
    Pepe, Alessio
    Usset, Antonella
    Manuguerra, Giovanna
    Savio, Giuseppina
    De Bella, Manuela Tamburo
    Laudani, Agata
    Alu, Massimo
    Cusimano, Maria Pia
    Scianna, Caterina
    Giresi, Armando
    Agostara, Biagio
    [J]. ONCOLOGY LETTERS, 2010, 1 (04) : 749 - 753
  • [7] Weekly paclitaxel and pegylated liposomal doxorubicin in metastatic breast carcinoma
    Leonardi, V.
    Palmisano, V.
    Pepe, A.
    Usset, A.
    Savio, G.
    Laudani, A.
    Calabria, C.
    Tartaglia, L.
    Amari, P.
    Carruba, G.
    Agostara, B.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 55 - 55
  • [8] A phase II study of bi-weekly pegylated liposomal doxorubicin and paclitaxel in metastatic breast canecer (MBC) patients (pts)
    Ferrari, Vittori D.
    Simoncini, Edda
    Amoroso, Vito
    Grisanti, Salvatore
    Valcamonico, Francesca
    Vassalli, Lucia
    Marpicati, Patrizia
    Rangoni, Giovanni
    Marini, Giovanni
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 49 - 49
  • [9] Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer
    Rivera, E
    Valero, V
    Arun, B
    Royce, M
    Adinin, R
    Hoelzer, K
    Walters, R
    Wade, JL
    Pusztai, L
    Hortobagyi, GN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) : 3249 - 3254
  • [10] Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study
    Collea, R. P.
    Kruter, F. W.
    Cantrell, J. E.
    George, T. K.
    Kruger, S.
    Favret, A. M.
    Lindquist, D. L.
    Melnyk, A. M.
    Pluenneke, R. E.
    Shao, S. H.
    Crockett, M. W.
    Asmar, L.
    O'Shaughnessy, J.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (10) : 2599 - 2605